Age Related Macular Degeneration Market Size, Share, Competitive Landscape and Trend Analysis Report, by Drug Type, by Disease Type, by Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

Key Market Dynamics 

As the global population experiencing a demographic shift toward older age groups, particularly in developed countries, the demand for AMD drugs is expected to rise. As a result, pharmaceutical companies have a larger target market and increased opportunities for revenue generation. Moreover, advancements in healthcare have led to longer life expectancies, further amplifying the need for effective AMD treatments to maintain quality of life in older adults.

However, a major restraint in the AMD drugs market is the issue of affordability and accessibility, particularly in developing regions. Many AMD drugs, such as anti-vascular endothelial growth factor (anti-VEGF) injections, are expensive and require frequent administration, making them financially burdensome for patients, especially in regions with limited healthcare coverage. Additionally, some treatments may not be widely accessible in rural areas or low-income countries due to infrastructural limitations. The high cost of treatment and limited access hinder patients from receiving timely and adequate care, impacting treatment outcomes and market growth. 

Furthermore, technological advancements and innovation present significant opportunities in the AMD drugs market. Advances in drug delivery systems, such as sustained-release implants and gene therapies, offer the potential for more effective and convenient treatment options. Innovative therapies targeting different pathways of AMD, including complement inhibition and neuroprotection, are under development, promising improved outcomes for patients. Moreover, the emergence of personalized medicine approaches allows for tailored treatments based on individual patient characteristics and disease subtypes, potentially enhancing efficacy and reducing side effects. Additionally, increase in investment in research and development, supported by collaborations between pharmaceutical companies and academic institutions, fosters a basis for discovering novel treatments and expanding the AMD drugs market.

Risk of getting advanced age-related macular degeneration for Age-related macular degeneration market 

The risk of advanced age-related macular degeneration (AMD) increases significantly with age. Individuals aged 50-59 have a relatively low risk of 2%, but this risk escalates substantially as age progresses. For those above 75, the risk soars to 30%. This data highlights the pressing need for effective treatments in the AMD drugs market. As the population ages, there's a growing demand for therapies that can prevent or manage AMD, a condition causing severe vision loss. Pharmaceutical companies focusing on AMD drugs face a considerable market opportunity, particularly in catering to the needs of older age groups where the risk is highest. 

Market Segmentation 

The age related macular degeneration industry is segmented into drug type, disease type, distribution channel, and region. On the basis of drug type, the market is categorized into aflibercept, ranibizumab and others. On the basis of disease type, the market is bifurcated into dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD) . On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Regional/Country Market Outlook 

The market outlook for age related macular degeneration market share across regions and countries, influenced by factors such as demographics, healthcare infrastructure, and access to treatments. Developed regions such as North America and Europe exhibit robust markets due to higher healthcare spending and aging populations. These regions often have advanced treatment options available and strong clinical research. Emerging markets in Asia-Pacific and Latin America are witnessing rapid growth, driven by increase in awareness, improvement in healthcare access, and rise in prevalence of AMD. However, challenges such as affordability and regulatory hurdles are expected to hamper market growth in these regions. Overall, the AMD drugs market presents opportunities for innovation and growth globally, with varying dynamics across different regions. 

According to an article by the World Health Organization (WHO) published in October 2022, it was estimated that 1 in 6 people in the world are expected to be aged 60 years or over by 2040. Age-related macular degeneration (AMD) is a leading cause of blindness and visual impairment among older adults, which may have a significant impact on their quality of life and ability to perform daily activities.

Industry Trends 

• On February 2023, Global vision and brain research non-profit BrightFocus Foundation celebrates the U.S. Food and Drug Administration’s (FDA) approval of Syfovre (pegcetacoplan injection) , the first-ever treatment to slow the progression of vision loss from geographic atrophy (GA) , an advanced form of dry age-related macular degeneration and a leading cause of blindness. 
• According to the factsheet published by Bright Focus Foundation in October 2022, about 11 million people in the U.S. have some form of age-related macular degeneration and this number is expected to double to nearly 22 million by 2050.

Competitive Landscape

The major players operating in the age related macular degeneration market size include Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Biogen, Bayer AG, Bausch Health Companies Inc, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals and Ionis Pharmaceuticals, Inc. Other players in the age-related macular degeneration market include IVERIC bio, Alcon, Allergan and so on. 

Recent Key Strategies and Developments 

• In October 2021, Roche announced that the U.S. Food and Drug Administration (FDA) has approved Susvim (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Wet AMD is a potentially blinding condition that requires treatment with eye injections as often as once a month. 
• In June 2021, Samsung Bioepis Co., Ltd. and Biogen Inc.  announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Byooviz, a biosimilar candidate referencing Lucentis 1 (ranibizumab) . Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular disorders, which are a leading cause of blindness. Byooviz has been recommended for approval for the treatment of neovascular (wet) age-related macular degeneration (AMD) . 
• In August 2022, Coherus BioSciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Cimerli (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab injection) . 

Key Sources Referred 

• World Health Organization (WHO)  
• Centers for Medicare & Medicaid Services (CMS)  
• National Health Service (NHS)  
• National Health Mission (NHM)  
• Centers for Disease Control and Prevention (CDC)  
• Food and Drug Administration (FDA)  
• National Institutes of Health (NIH)  
• Coherus BioSciences, Inc. 
• Mental Health Foundation 

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the age related macular degeneration market analysis from 2024 to 2033 to identify the prevailing age related macular degeneration market opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the age related macular degeneration industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global age related macular degeneration market trends, key players, market segments, application areas, and market growth strategies.